Glycomimetics: Innovation today, hope for healing tomorrow.

Headquartered in Gaithersburg, Maryland, GlycoMimetics is a publicly traded, clinical-stage biotechnology company that utilizes novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs. The company’s mission is to continue to advance its pipeline, providing hope for patients with sickle cell, cancer, and other serious diseases.

Glycomimetics Facts
GLYC Stock Activity
Glycomimetics Product


In October 2011, GlycoMimetic entered into an exclusive worldwide licensing agreement with Pfizer, Inc. to develop GlycoMimetic’s lead drug candidate, Rivipansel, a treatment for vaso-occlusive crisis (VOC) associated with sickle cell disease. The potential value of the agreement for GlycoMimetics is approximately $340 million, including an upfront payment as well as developmental, regulatory, and commercial milestones.